Feb 17,2017

BD to Present at Investor Healthcare Conferences

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 17,2017

Insulet Presents Strong Omnipod® Horizon™ Hybrid Closed-Loop Study Results at ATTD in Paris

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced positive results from the first feasibility study of the Omnipod Horizon™ hybrid closed-loop system. Study participants included 24 adults with type 1 diabetes. The 36-hour study1 included a modified version of Insulet's Omnipod, a Dexcom® continuous glucose sensor, and Insulet's personalized model predictive control algorithm. Results showed use of the Company's hybrid closed-loop system was associated with significantly less time spent in hypoglycemic blood glucose range compared to ranges prior to the study.

CLINICAL STUDY

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 20,2017

Brighter signs agreement with Sonat for global logistics solution

Brighter has selected Sonat as its development partner for the upcoming launch of Actiste®, Brighter’s connected diabetes solution. Sonat specializes in developing, managing and running logistics processes, and will together with Brighter develop a strong logistics platform that facilitates growth and international expansion.

COLLABORATION PARTNERSHIP

#r&d

#bgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Feb 21,2017

Tandem Diabetes Care Schedules Fourth Quarter and Full Year 2016 Earnings Press Release and Conference Call

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its fourth quarter and full year 2016 results after the financial markets close on Wednesday, March 8, 2017. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its fourth quarter and full year 2016 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Feb 27,2017

Insulet Reports Fourth Quarter and Full Year 2016 Financial Results

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2016. The company's fourth quarter 2016 revenue increased 24% to $103.6 million, compared to $83.8 million in the fourth quarter of 2015. For the year ended December 31, 2016, revenue increased 39% to $367.0 million, compared to revenue of $263.9 million in 2015.

View Analyst & Ambassador Comments
Go to original news
Mar 09,2017

Researchers build 4mm patch that monitors glucose from sweat, delivers drugs

As exciting as the near future of diabetes management is, with numerous efforts underway to perfect closed-loop CGM and pump systems for automated insulin delivery, the systems of the future could be even easier. A paper in Science Advances details the prototype for a 4 millimeter wearable patch that could not only noninvasively detect glucose levels from sweat, but also deliver the diabetes medication Metformin through microneedles in response to the sensor's readings.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 13,2017

Data show gamified, personal coaching program SidekickHealth a good complement to in-person DPPs

Digital coaching and a gamified approach to healthy lifestyle choices may be a powerful tool in managing chronic conditions, according to new data from health engagement platform provider GoodlifeMe, which makes SidekickHealth. Goodlifeme, based in Gothenburg, produces a mobile-based health program, SidekickHealth, and also has a large part of the business operations run through its subsidiary in Iceland. Over the past year, SidekickHealth was deployed across many in-person, community-based diabetes prevention programs across the country including several for populations with added challenges such as language barriers or old age.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 16,2017

Livongo's $52.5M round will take it beyond diabetes and beyond the US

Technology-enabled diabetes management company Livongo Health has raised $52.5 million in new funding in a round co-led by General Catalyst, an existing investor, and international investment company Kinnevik. Other investors included Microsoft Ventures, American Investment Holdings, and EDBI, a Singapore-based fund whose portfolio includes WellTok, GoBalto, and Sotera Wireless. All previous investors also participated in the round.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Mar 02,2017

Tandem Diabetes Care Launches First Ever Remote Software Update for Insulin Pump using a Personal Computer

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the release of a software update for t:slim® Insulin Pumps purchased before April 2015.

PRODUCT

#mobile app

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 08,2017

Tandem Diabetes Care Reports 2016 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the year and quarter ended December 31, 2016 and provided financial guidance for the year ending December 31, 2017. Pump shipments grew 9 percent to 16,938 for the year ended December 31, 2016 compared to 15,483 pumps shipped in 2015. GAAP sales grew 16 percent to $84.2 million for the year ended December 31, 2016 compared to $72.9 million for 2015.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES